



Contacts

Business Development & Licensing



Rok Ocvirk, PhD ACMA

Director Licensing

Mobile: +33 7 88 44 12 36

rok.ocvirk@servier.com

Research & Development



David Theron, Pharm.D

Director of Opportunities

Mobile: +33 6 49 55 11 98

david.theron@servier.com



Clément Gautier, Ph.D

External Innovation Scout

Mobile: +33 6 76 64 22 24

clement.gautier@servier.com

Active CNS Partnerships



Areas of interest

- Partners looking for accelerative collaboration and clinical enablement
- Targeting sub-populations and rare forms of neurodegenerative disease

Target-to-hit up to lead optimisation stage

Biological mechanisms

Normalising disease-disrupted protein homeostasis

- Clearance
- Autophagic
- Lysosomal Network
- Proteasome
- Protein/RNA expression regulation

Target class

Targeting DNA/RNA/ proteins genetically and causally linked to disease

Indications

- Synucleinopathies
- Amyotrophic lateral sclerosis
- Tauopathies
- PolyQ diseases

Modality

- ASO
- Gene therapy
- Small molecules
- PROTAC

Drug delivery

- Central administration
- Brain distribution and targeted delivery (formulation)
- Technologies to improve the efficacy/specificity of cellular delivery (ASO/AAV)

Exclusions

- Epilepsy, multiple sclerosis, pain, psychiatry, infectious diseases
- Antibodies, cell therapy, vaccination

Partnering with Servier

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose — contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

A PARTNER OF CHOICE

A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

A partner with a global presence

With €4.6Bn of revenue in 2018/2019 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners

A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets

Our areas of interest



Cardiovascular diseases

- Heart failure (acute and chronic HF)
- Atrial fibrillation
- Systemic hypertension
- Coronary artery disease
- Arrhythmic Cardiomyopathies
- Hyperlipidemia
- Venous diseases



Metabolism

- Type 2 Diabetes
- NASH
- Diabetic Kidney Diseases
- **Clinical & Marketing Stage:**
 - Diabetic retinopathy
 - Non-injectable Insulins



Oncology

Late stage opportunities

Solid tumors; priority GI (CRC, HCC, pancreas, gastric, esophageal, cholangiocarcinoma)
Other indications would be considered if biomarker-selected populations exist
Pediatric cancers
Hematologic cancers (in particular NHL, ALL and AML)

Discovery & Early Clinical Focus

Cancer cell Signaling

- Apoptosis (BCL2 family; extrinsic cell death)
- Novel oncogenes, oncogene stability regulators
- Epigenetic regulators (with biomarker validation)
- Synthetic lethality associated with genetic defect

Immuno-oncology

- T cell activation
- Immunosuppression
- Innate immunity
- Tumor micro-environment



Immuno-inflammatory diseases

Inflammatory & autoimmune disease

- Lupus
- Primary Sjögren syndrome
- Systemic sclerosis



Central Nervous System

- Parkinson's disease
- Autism
- Alzheimer's disease
- ALS
- Huntington disease
- Other rare disease in neurodevelopmental and neurodegenerative disorders



Enabling technologies

- Solutions to improve solubility
- Oral administration of peptides
- Blood-brain barrier penetration systems
- Nose-to-brain delivery solutions
- Cardiac drug delivery
- Micro-needle
- Acid nucleic delivery
- Galenic micro-electronics
- Innovative polymer for improved drug delivery